Hutchmed (China) Limited Director's Share Dealing (4497M)

TIDMHCM

RNS Number : 4497M

Hutchmed (China) Limited

14 September 2023

Director's Share Dealing

Hong Kong, Shanghai & Florham Park, NJ - Thursday, September 14, 2023: HUTCHMED (China) Limited (" HUTCHMED " or the "Company") (Nasdaq/AIM: HCM; SEHK:13) has received notifications that the spouse of Mr Graeme Jack, Independent Non-executive Director, sold a total of 3,000 American Depositary Shares of the Company ("ADSs", each representing five Ordinary Shares of US$0.10 each of the Company) at a price of US$14.70 per ADS on September 12, 2023.

Following the above sale of 3,000 ADSs, the holding of Mr Jack is 17,339 ADSs (Note) , representing approximately 0.01% of the current issued share capital of the Company.

Note: 17,339 ADSs included (i) 9,128 ADSs currently held by Mr Jack and (ii) 8,211 ADSs as beneficiary of a trust under long term incentive plan.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 
 1      Details of the person discharging managerial responsibilities/person closely associated 
 
   a)     Name                                Ms Debbie Sue Chung 
       ----------------------------------  --------------------------------------------------------------------------- 
 2      Reason for the notification 
       --------------------------------------------------------------------------------------------------------------- 
 
   a)     Position/status                     Spouse of Mr Graeme Jack, Independent Non-executive Director 
       ----------------------------------  --------------------------------------------------------------------------- 
 
   b)     Initial notification/Amendment      Initial notification 
       ----------------------------------  --------------------------------------------------------------------------- 
 3      Details of the issuer, emission allowance market participant, auction platform, auctioneer 
         or auction monitor 
       --------------------------------------------------------------------------------------------------------------- 
 
   a)     Name                                HUTCHMED (China) Limited 
       ----------------------------------  --------------------------------------------------------------------------- 
 
   b)     LEI                                 2138006X34YDQ6OBYE79 
       ----------------------------------  --------------------------------------------------------------------------- 
 4      Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
         each type of transaction; (iii) each date; and (iv) each place where transactions have been 
         conducted 
       --------------------------------------------------------------------------------------------------------------- 
 
   a)    Description of the financial         ADS each representing five Ordinary Shares of US$0.10 each 
         instrument, type of instrument 
 
         Identification code 
                                              ADS ISIN: US44842L1035 
       ----------------------------------  --------------------------------------------------------------------------- 
 
   b)     Nature of the transaction           Sale of 3,000 ADSs on September 12, 2023 at a price of US$14.70 per ADS. 
       ----------------------------------  --------------------------------------------------------------------------- 
 
                                              Price(s)                             Volume(s) 
                                             -----------------------------------  ---------------------------------- 
                                              US$14.70                             3,000 ADSs 
                                             -----------------------------------  ---------------------------------- 
 c)     Price(s) and volume(s) 
       ----------------------------------    -----------------------------------  ---------------------------------- 
 
 
 
   d)      Aggregated information        N/A 
           -  Aggregated volume 
           -  Price 
 
   e)      Date of the transaction       2023-09-12 
        ----------------------------  ---------------------- 
 
   f)      Place of the transaction      Nasdaq Stock Market 
        ----------------------------  ---------------------- 
 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn.

Contacts

 
Investor Enquiries 
Mark Lee, Senior Vice President                    [phone] 
Annie Cheng, Vice President                        [phone] 
 
Media Enquiries 
Ben Atwell / Alex Shaw,                            [phone] / [phone] (Mobile) / [phone] 
 FTI Consulting                                    (Mobile) 
                                                   [e-mail] 
Zhou Yi,                                           [phone] (Mobile) 
 Brunswick                                          [e-mail] 
 
Nominated Advisor 
Atholl Tweedie / Freddy Crossley / Daphne Zhang, 
 Panmure Gordon                                    [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHNKQBBOBKKKCD

(END) Dow Jones Newswires

September 14, 2023 04:30 ET (08:30 GMT)